Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide
Diabetes Care Jul 24, 2019
Rosenstock J, et al. - In early type 2 diabetes (T2D) (drug naive or on metformin monotherapy), researchers tested once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA) for its effectiveness, safety, and tolerability. For this analysis, patients, of whom ∼90% were on metformin monotherapy, were randomized to 1 of 5 efpeglenatide doses (0.3, 1, 2, 3, or 4 mg QW; n=181), placebo (n=37), or liraglutide (≤1.8 mg daily; n=36). According to findings, once a week, ephpeglenatide resulted in significant decreases in HbA1c and weight. The safety profile was consistent with the GLP-1 RA class in patients with early T2D primarily under metformin monotherapy. With efpeglenatide, no neutralizing antibodies were identified.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries